Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis.
Since high levels of serum IL-6 predict a poor prognosis of patients with multiple myeloma (MM), we investigated if a related cytokine, oncostatin M (OSM), correlates with clinical or biochemical findings or has prognostic significance in patients with MM. Among 82 newly diagnosed MM patients, OSM was detected in the sera in 45 (55%). Serum OSM had a borderline statistical correlation with serum IL-6 (r = 0.198, p = 0.074) and C-reactive protein (r = 0.199, p = 0.074) concentrations. However, OSM did not have prognostic significance alone or in combination with other factors. The median survival of patients with detectable serum OSM concentration was 41 months (range 2-124 months) and of OSM negative patients 35 months (1-75 months). Serum OSM concentration was not associated with clinical factors or severity of bone disease at diagnosis. We conclude that serum OSM concentration is not a prognostic factor in MM patients.
Koskela
K
K
Department of Medicine, Turku University Central Hospital, Finland.
Pelliniemi
T T
TT
Rajamäki
A
A
Pulkki
K
K
Remes
K
K
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications / Q000401:mortality; D009363:Neoplasm Proteins / Q000097:blood*; D053683:Oncostatin M; D010014:Osteolysis / Q000097:blood / Q000209:etiology; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D015850:Interleukin-6; D009363:Neoplasm Proteins; C508351:OSM protein, human; D010455:Peptides; D053683:Oncostatin M; D002097:C-Reactive Protein